BTTX Insider Trading Activity and SEC Form 4 Filings
BTTX insider trading summary
No open-market insider purchases or sales of Better Therapeutics, Inc. (BTTX) have been reported on SEC Form 4 in the past 12 months.
Latest BTTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 27, 2023 | Geoffrey M. Parker | Insider | Buy | $500K (685,025 @ $0.73) |
| Jul 27, 2023 | Frank Karbe | Chief Executive Officer | Buy | $100K (137,005 @ $0.73) |
| Jul 27, 2023 | David P Perry | Executive Chairman | Buy | $900K (1,233,045 @ $0.73) |
| Jul 27, 2023 | Elder Granger | Insider | Buy | $25K (34,251 @ $0.73) |
| Jul 27, 2023 | Andrew J. Armanino | Insider | Buy | $200K (274,010 @ $0.73) |
| Jul 27, 2023 | Mark A. Berman | Chief Medical Officer | Buy | $40K (54,802 @ $0.73) |
| May 16, 2023 | Elder Granger | Insider | Buy | $520 (600 @ $0.87) |
| Apr 10, 2023 | David P. Perry 2015 Trust | 10% Owner | Buy | $1.1M (1,333,333 @ $0.82) |
| Apr 10, 2023 | David P. Perry 2015 Trust | 10% Owner | Buy | $3.0M (3,636,364 @ $0.82) |
| Apr 10, 2023 | David P Perry | See Remarks | Buy | $1.1M (1,333,333 @ $0.82) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.